🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "significant breakthrough" in the fight against drug-resistant strains of the bacteria, according to researchers.

A Global Challenge

Cases of gonorrhoea are increasing around the world, with figures suggesting more than 82 million infections annually. Particularly high rates are observed in Africa and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a all-time high, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely step in the reality of growing infection rates, the spread of superbugs and the very limited treatment choices presently on offer.”

Health officials are particularly alarmed about the increase in drug-resistant strains. The global health body has designated it as a "critical concern". Recent surveillance revealed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Therapies Gain Approval

Zoliflodacin, alternatively called a brand name, was cleared by the US Food and Drug Administration in mid-December for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Scientists anticipate that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GSK, also received approval in the same week. This drug, which is also used to treat urinary tract infections, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a unique collaborative effort for antibiotic development. The charitable organization GARDP partnered with the drug firm its industry partner to develop it.

“This milestone marks a major breakthrough in the therapy of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Research Study Outcomes and Worldwide Availability

According to results published in a prominent scientific publication, zoliflodacin cured the vast majority of uncomplicated infections. This puts it on an equal footing with the typical regimen, which uses a dual-drug approach. The trial included over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the authority to register and commercialise the drug in many regions with limited resources.

Medical professionals treating patients have voiced optimism. Access to a single-dose, oral treatment of this kind is hailed as a "critical tool" for gonorrhoea control. This is viewed as crucial to lessen the impact of the illness for patients and to halt the transmission of extremely resistant gonorrhoea worldwide.